Genentech s Evrysdi Continues to Improve Motor Function and Survival in Babies With Type 1 Spinal Muscular Atrophy (SMA)
- Evrysdi increased survival and reduced need for permanent ventilation -
- Evrysdi has proven efficacy across adults, children and babies 2 months and older -
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) today announced new 2-year data from Part 2 of FIREFISH, a Phase 2/3 global study evaluating Evrysdi (risdiplam) in infants aged 1-7 months at enrollment with symptomatic Type 1 spinal muscular atrophy (SMA). The data showed Evrysdi continued to improve motor function between months 12 and 24, including the ability to sit without support. The study also showed Evrysdi continued to improve survival, improve ability to feed orally and reduce the need for permanent ventilation . Exploratory data suggested Evrysdi continued to improve the ability to swallow and reduce hospitalizations compared to the natural course of Type 1 SMA. Safety for E
Roche : FDA Approves Xolair (omalizumab) Prefilled Syringe for Self-Injection Across All Indications marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
Date Time
Share
Myovant Sciences and Pfizer Announce First Participant Dosed in Phase 3 SERENE Study Evaluating Contraceptive Efficacy of Once-Daily
SERENE is a Phase 3 single-arm, open-label study evaluating the contraceptive efficacy of investigational relugolix combination tablet in sexually active, healthy women ages 18-35 years
Contraceptive potential of relugolix combination tablet supported by prior Phase 1 study that demonstrated 100% ovulation inhibition
Data would support a potential indication of pregnancy prevention for women treated with relugolix combination tablet, if approved
BASEL, Switzerland and NEW YORK, April 12, 2021 (GLOBE NEWSWIRE) Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced that the first participant has been dosed in the Phase 3 SERENE study evaluating the contraceptive efficacy of relugolix combination tablet (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg) in healthy women ages 18-35 years who are
Porex Life Sciences Institute Establishes Innovation Center to Address Market Demand for New Life Sciences Technologies
The Porex Life Sciences Institute Launches Saletto™ Oral Fluid Collection Device
News provided by
Share this article
Share this article
ATLANTA, April 12, 2021 /PRNewswire/ Filtration Group a global leader producing best-in-class filtration solutions to make the world safer, healthier and more productive today announced the launch of the Porex Life Sciences Institute, a new business unit dedicated to the advancement of life science technologies.
The Porex Life Sciences Institute is located in close proximity to Atlanta s med-tech innovation corridor. The Institute will serve the burgeoning life science market by providing end-users with integrated solutions that are enabled by porous polymers.
Myovant Sciences and Pfizer Announce First Participant Dosed in Phase 3 SERENE Study Evaluating apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.